219 related articles for article (PubMed ID: 31190905)
61. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
62. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Restelli U; Alberti A; Lazzarin A; Bonfanti M; Nappi C; Croce D
Eur J Health Econ; 2018 Jan; 19(1):37-44. PubMed ID: 28008546
[TBL] [Abstract][Full Text] [Related]
63. Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial.
Golan Y; Tang Y; Mt-Isa S; Wan H; Teal V; Badshah C; Dadwal S
Pharmacoecon Open; 2021 Sep; 5(3):469-473. PubMed ID: 33871830
[TBL] [Abstract][Full Text] [Related]
64. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model.
Stollenwerk B; Bartmus T; Klug F; Stock S; Müller D
Osteoporos Int; 2015 Apr; 26(4):1367-79. PubMed ID: 25572047
[TBL] [Abstract][Full Text] [Related]
65. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
66. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
67. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
68. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
69. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection.
Cassaniti I; Colombo AA; Bernasconi P; Malagola M; Russo D; Iori AP; Girmenia C; Greco R; Peccatori J; Ciceri F; Bonifazi F; Percivalle E; Campanini G; Piccirilli G; Lazzarotto T; Baldanti F
Am J Transplant; 2021 Apr; 21(4):1622-1628. PubMed ID: 33320429
[TBL] [Abstract][Full Text] [Related]
70. Cost-effectiveness analysis of invasive EEG monitoring in drug-resistant epilepsy.
Kovács S; Tóth M; Janszky J; Dóczi T; Fabó D; Boncz I; Botz L; Zemplényi A
Epilepsy Behav; 2021 Jan; 114(Pt A):107488. PubMed ID: 33257296
[TBL] [Abstract][Full Text] [Related]
71. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
Kim T; Lee YM; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Jung JH; Shin S; Kim YH; Kang YA; Lee YS; Lee JH; Lee JH; Lee KH; Park SK; Han DJ; Kim SH
Korean J Intern Med; 2016 Sep; 31(5):961-70. PubMed ID: 27055664
[TBL] [Abstract][Full Text] [Related]
72. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Deleenheer B; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
[TBL] [Abstract][Full Text] [Related]
74. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
75. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.
Moore RD; Chaisson RE
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):15-21. PubMed ID: 9377120
[TBL] [Abstract][Full Text] [Related]
76. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
77. Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency.
Popping S; Dalm VASH; Lübke N; Cristanziano VD; Kaiser R; Boucher CAB; Van Kampen JJA
Open Forum Infect Dis; 2019 Sep; 6(9):ofz375. PubMed ID: 31660414
[TBL] [Abstract][Full Text] [Related]
78. A Cost-Effectiveness Analysis of the Swedish Universal Parenting Program All Children in Focus.
Ulfsdotter M; Lindberg L; Månsdotter A
PLoS One; 2015; 10(12):e0145201. PubMed ID: 26681349
[TBL] [Abstract][Full Text] [Related]
79. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]